Thus, GLP-1 agonists have been approved for therapy in T2D (type 2 diabetes) and employed with discrete results to overcome insulin resistance to decrease the appetite and favor weight loss, but they can also be useful in reducing cardiovascular events and mortality, according to a recent meta-analysis [113]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.